Brański 𝔯𝔞𝔯𝔢 𝔥𝔲𝔪𝔞𝔫 (@vxel) 's Twitter Profile
Brański 𝔯𝔞𝔯𝔢 𝔥𝔲𝔪𝔞𝔫

@vxel

Zarząd WP Holding, CEO Audioteka & Pilot WP; książki, debiasing, wrongthink. Zdyscyplinowany agent chaosu. Bullish bear. Bleed green! Celtics ☘️ & 📈

ID: 2579931

linkhttps://michalb.notion.site/ma-pa-z-brzytw-a03c546fac4b425f88ebb7b5a65aacab calendar_today28-03-2007 00:22:37

34,34K Tweet

9,9K Followers

3,3K Following

Hugh (@hmbrough_) 's Twitter Profile Photo

Bro got an Ottoman Sultan-sized harem through a Pokémon game community, meanwhile Silicon Valley tech execs are writing War and Peace in a dating document and getting nothing.

Justine Moore (@venturetwins) 's Twitter Profile Photo

Every autistic person I know loves AI. Many of them use LLMs more than anyone else I've seen - and find it incredibly useful in their personal and professional lives. I think it's weird we don't talk about this more.

Every autistic person I know loves AI. 

Many of them use LLMs more than anyone else I've seen - and find it incredibly useful in their personal and professional lives. 

I think it's weird we don't talk about this more.
Antoine (@antoine_os) 's Twitter Profile Photo

The biggest mistake in thinking about AI and robots? expecting it to act human. It won’t and that’s exactly why it’ll be 1000× more capable i.e. this RC helicopter shows what machines can do when you remove the anthropomorphism layer in your expectations

Crémieux (@cremieuxrecueil) 's Twitter Profile Photo

This is a good illustration of a general principle: As you build new high-end apartments, people move up, freeing up supply of lower-tier apartments. Building luxury housing thus lowers downmarket rents. You don't need to build 'affordable housing' to make housing affordable.

This is a good illustration of a general principle:

As you build new high-end apartments, people move up, freeing up supply of lower-tier apartments.

Building luxury housing thus lowers downmarket rents. You don't need to build 'affordable housing' to make housing affordable.
Eric Topol (@erictopol) 's Twitter Profile Photo

The potency of the GLP-1 drugs for weight loss keeps increasing. Retatrutide is a triple receptor agonist with no clearcut plateau. There are already quadruple receptors in the pipeline. economist.com/the-world-ahea…

The potency of the GLP-1 drugs for weight loss keeps increasing. Retatrutide is a triple receptor agonist with no clearcut plateau. There are already quadruple receptors in the pipeline.
economist.com/the-world-ahea…
Hensen Juang (@basedjensen) 's Twitter Profile Photo

Twitter seem to be only now finding about these bad boys. It has been around for some time and it's insane what people can do with them

Brański 𝔯𝔞𝔯𝔢 𝔥𝔲𝔪𝔞𝔫 (@vxel) 's Twitter Profile Photo

<<“Historically, capital was the bottleneck,” says one investor in several big-name hedge funds, who asked to remain anonymous in order to speak candidly. “Now it's 100% talent.”>> bloomberg.com/opinion/newsle…

Rob Henderson (@robkhenderson) 's Twitter Profile Photo

For young adults, by far the most common number of sex partners in the past year is zero or one. About 10-20% of the young adult population has lots of sex with each other, while the rest are either sexless or in committed relationships. stevestewartwilliams.com/p/12-new-findi…

For young adults, by far the most common number of sex partners in the past year is zero or one. About 10-20% of the young adult population has lots of sex with each other, while the rest are either sexless or in committed relationships. stevestewartwilliams.com/p/12-new-findi…
Kim Nielsen (@knielsen2000) 's Twitter Profile Photo

Colon cancer patients using either Semaglutide or Tirzepatide, were less than half as likely to die within five years compared to those not using the drugs (15.5% versus 37.1%) Yet Another new set of data, that keep pushing the GLP1 class towards the “wonder” drug labelling.

Colon cancer patients using either Semaglutide or Tirzepatide, were less than half as likely to die within five years compared to those not using the drugs (15.5% versus 37.1%)

Yet Another new set of data,  that keep pushing the GLP1 class towards the “wonder” drug labelling.